{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04731376",
            "orgStudyIdInfo": {
                "id": "STUDY00001062"
            },
            "secondaryIdInfos": [
                {
                    "id": "NCI-2020-06998",
                    "type": "REGISTRY",
                    "domain": "CTRP (Clinical Trial Reporting Program)"
                },
                {
                    "id": "EU5097-20",
                    "type": "OTHER",
                    "domain": "Emory University Hospital/Winship Cancer Institute"
                },
                {
                    "id": "P30CA138292",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/P30CA138292"
                }
            ],
            "organization": {
                "fullName": "Emory University",
                "class": "OTHER"
            },
            "briefTitle": "Perioperative Testosterone Replacement Therapy for the Improvement of Post-Operative Outcomes in Patients With Low Testosterone",
            "officialTitle": "Perioperative Testosterone Replacement Therapy Improves Outcomes: A Pilot Safety and Feasibility Study",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "perioperative-testosterone-replacement-therapy-for-the-improvement-of-post-operative-outcomes-in-patients-with-low-testosterone"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-01",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-01-25",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-10-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-10-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-01-13",
            "studyFirstSubmitQcDate": "2021-01-28",
            "studyFirstPostDateStruct": {
                "date": "2021-02-01",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-01-12",
            "lastUpdatePostDateStruct": {
                "date": "2024-01-17",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Kenneth Ogan",
                "investigatorTitle": "Principal Investigator",
                "investigatorAffiliation": "Emory University"
            },
            "leadSponsor": {
                "name": "Emory University",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "National Cancer Institute (NCI)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This phase I trial investigates the safety of testosterone replacement therapy around the time of major urologic surgery (perioperative) in order to improve quality of life and post-operative outcomes such as decreased length of hospital stay, complications, and mortality in patients with low testosterone levels. Studies have demonstrated that patients undergoing testosterone replacement therapy have increased lean body mass, decreased fat mass and have improved physical function. Testosterone replacement therapy can also stimulate bone formation and may decrease the risk of fracture. Information from this trial may be used to support the incorporation of testosterone level testing and testosterone replacement into the perioperative treatment decision-making process.",
            "detailedDescription": "PRIMARY OBJECTIVE:\n\nI. To examine the safety and feasibility of perioperative testosterone replacement (TR) therapy in hypogonadal male patients undergoing major operations.\n\nOUTLINE: Patients are assigned to 1 of 2 arms.\n\nARM I: Patients with low testosterone levels receive testosterone cypionate intramuscularly (IM) once a week (QW) for 3 months in the absence of disease progression or unacceptable toxicity.\n\nARM II: Patients with normal testosterone levels receive standard peri-operative care."
        },
        "conditionsModule": {
            "conditions": [
                "Hypogonadism",
                "Malignant Urinary System Neoplasm",
                "Urinary System Disorder",
                "Urinary System Neoplasm"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "SUPPORTIVE_CARE",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 100,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Arm I (testosterone cypionate)",
                    "type": "EXPERIMENTAL",
                    "description": "Patients with low testosterone levels receive testosterone cypionate IM QW for 3 months.",
                    "interventionNames": [
                        "Procedure: Quality-of-Life Assessment",
                        "Other: Questionnaire Administration",
                        "Drug: Testosterone Cypionate"
                    ]
                },
                {
                    "label": "Arm II (best practice)",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Patients with normal testosterone levels receive standard peri-operative care.",
                    "interventionNames": [
                        "Other: Best Practice",
                        "Procedure: Quality-of-Life Assessment",
                        "Other: Questionnaire Administration"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "OTHER",
                    "name": "Best Practice",
                    "description": "Receive standard peri-operative care",
                    "armGroupLabels": [
                        "Arm II (best practice)"
                    ],
                    "otherNames": [
                        "standard of care",
                        "standard therapy"
                    ]
                },
                {
                    "type": "PROCEDURE",
                    "name": "Quality-of-Life Assessment",
                    "description": "Ancillary studies",
                    "armGroupLabels": [
                        "Arm I (testosterone cypionate)",
                        "Arm II (best practice)"
                    ],
                    "otherNames": [
                        "Quality of Life Assessment"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Questionnaire Administration",
                    "description": "Ancillary studies; Quality of life questionnaires will be given both preoperatively and at 3-months postoperatively",
                    "armGroupLabels": [
                        "Arm I (testosterone cypionate)",
                        "Arm II (best practice)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Testosterone Cypionate",
                    "description": "Given IM",
                    "armGroupLabels": [
                        "Arm I (testosterone cypionate)"
                    ],
                    "otherNames": [
                        "depAndro",
                        "Depo-Testosterone",
                        "Depotest",
                        "Depovirin",
                        "Pertestis",
                        "Virilon"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Changes in quality of life before and after surgery",
                    "description": "The Patient Reported Outcomes Measurement Information System (PROMIS Global Health-10) is a 10 question survey that uses questions concerning physical function, overall quality of life, physical health, mood, ability to participate in social roles and activities, pain and fatigue to arrive at a score between 10 and 50. Patient's score are the outcome we will measure.",
                    "timeFrame": "Baseline to 3 months"
                },
                {
                    "measure": "Change in frailty phenotype before and after surgery",
                    "description": "The Fried Frailty Criteria uses a comorbidity scale, measures of activity, physical tests of strength and speed, nutritional status and anatomic features to produce a score from 0-5. These numbers correspond with the following frailty categorizations: non-frail (score 0), pre-frail (score 1-2) and frail (score 3-5). This score represents one outcome measure.",
                    "timeFrame": "Baseline, post operative refers to the period after the procedure until final follow up and study completion. Will occur an average of 90 days after the procedure."
                },
                {
                    "measure": "Major complications",
                    "description": "Major complication considered Clavien-Dindo IIIb and above.",
                    "timeFrame": "Within 90 days of surgery"
                },
                {
                    "measure": "Minor complications",
                    "description": "Minor complication considered Clavien-Dindo IIIb and below.",
                    "timeFrame": "Within 90 days of surgery"
                },
                {
                    "measure": "Rate of intensive care unit (ICU) admission",
                    "description": "Admissions to the ICU between post-op day 1 to 90 days post surgery",
                    "timeFrame": "Up to 3 months post-surgery"
                },
                {
                    "measure": "Hospital length of stay",
                    "description": "Number of days stayed in the hospital after surgery",
                    "timeFrame": "Up to 3 months post-operative"
                },
                {
                    "measure": "Discharge disposition",
                    "description": "Determined by if patient is discharged to home, to home with services, or to facility.",
                    "timeFrame": "Discharge from hospital"
                },
                {
                    "measure": "Unplanned readmissions",
                    "description": "Readmissions to hospital after discharge within 90 days",
                    "timeFrame": "Within 90 days of surgery"
                },
                {
                    "measure": "Mortality rate",
                    "description": "Rate of patient deaths after surgery",
                    "timeFrame": "Within 90 days of surgery"
                },
                {
                    "measure": "Testosterone level",
                    "description": "Levels of Testosterone determined by laboratory blood draw",
                    "timeFrame": "Up to 3 months post-operative"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients already scheduled for major surgery requiring an overnight hospital stay\n* Patients must be able to give informed consent\n* Patients must be willing to do study's preoperative and post-operative assessment tools\n\nExclusion Criteria:\n\n* Patient with history of prostatectomy with detectable prostate specific antigen (PSA)\n* Patient with history of prostate radiation/chemotherapy treatment and has experienced bounce or rise in PSA\n* Patients with history of/undergoing orchiectomy\n* Patients undergoing hormone replacement therapy currently or history of testosterone use within last year\n* Patients who use anabolic steroids\n* Patients with history of solitary or undescended testis\n* Patients with history of pituitary disorders\n* Patients with history of thromboembolic events in last year\n* Patients with hematocrit \\> 55%\n* Patients with uncontrolled congestive heart failure\n* Special populations: Adults unable to consent, individuals who are not yet adults (infants, children, teenagers), pregnant women and prisoners",
            "healthyVolunteers": false,
            "sex": "MALE",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Kenneth Ogan, MD",
                    "role": "CONTACT",
                    "phone": "404-778-3038",
                    "email": "kogan@emory.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Kenneth Ogan, MD",
                    "affiliation": "Emory University Hospital/Winship Cancer Institute",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Emory University Hospital/Winship Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Atlanta",
                    "state": "Georgia",
                    "zip": "30322",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Mersiha Torlak",
                            "role": "CONTACT",
                            "phone": "404-778-4823",
                            "email": "mersiha.torlak@emory.edu"
                        },
                        {
                            "name": "Kenneth Ogan, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.749,
                        "lon": -84.38798
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000014571",
                    "term": "Urologic Neoplasms"
                },
                {
                    "id": "D000014570",
                    "term": "Urologic Diseases"
                },
                {
                    "id": "D000007006",
                    "term": "Hypogonadism"
                }
            ],
            "ancestors": [
                {
                    "id": "D000006058",
                    "term": "Gonadal Disorders"
                },
                {
                    "id": "D000004700",
                    "term": "Endocrine System Diseases"
                },
                {
                    "id": "D000014565",
                    "term": "Urogenital Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000052776",
                    "term": "Female Urogenital Diseases"
                },
                {
                    "id": "D000005261",
                    "term": "Female Urogenital Diseases and Pregnancy Complications"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000052801",
                    "term": "Male Urogenital Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M17320",
                    "name": "Urologic Neoplasms",
                    "asFound": "Urinary System Neoplasm",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10056",
                    "name": "Hypogonadism",
                    "asFound": "Hypogonadism",
                    "relevance": "HIGH"
                },
                {
                    "id": "M17319",
                    "name": "Urologic Diseases",
                    "asFound": "Urinary System Disorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9163",
                    "name": "Gonadal Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M7862",
                    "name": "Endocrine System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M17315",
                    "name": "Urogenital Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27093",
                    "name": "Female Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14127",
                    "name": "Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M8399",
                    "name": "Female Urogenital Diseases and Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M27095",
                    "name": "Male Urogenital Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008777",
                    "term": "Methyltestosterone"
                },
                {
                    "id": "D000013739",
                    "term": "Testosterone"
                },
                {
                    "id": "C000010792",
                    "term": "Testosterone undecanoate"
                },
                {
                    "id": "C000004648",
                    "term": "Testosterone enanthate"
                },
                {
                    "id": "C000016131",
                    "term": "Testosterone 17 beta-cypionate"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000728",
                    "term": "Androgens"
                },
                {
                    "id": "D000006728",
                    "term": "Hormones"
                },
                {
                    "id": "D000006730",
                    "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018931",
                    "term": "Antineoplastic Agents, Hormonal"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000045930",
                    "term": "Anabolic Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11751",
                    "name": "Methyltestosterone",
                    "asFound": "CBT",
                    "relevance": "HIGH"
                },
                {
                    "id": "M16509",
                    "name": "Testosterone",
                    "asFound": "CBT",
                    "relevance": "HIGH"
                },
                {
                    "id": "M223475",
                    "name": "Testosterone undecanoate",
                    "asFound": "CBT",
                    "relevance": "HIGH"
                },
                {
                    "id": "M223485",
                    "name": "Testosterone enanthate",
                    "asFound": "CBT",
                    "relevance": "HIGH"
                },
                {
                    "id": "M235012",
                    "name": "Testosterone 17 beta-cypionate",
                    "asFound": "CBT",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4059",
                    "name": "Androgens",
                    "relevance": "LOW"
                },
                {
                    "id": "M9789",
                    "name": "Hormones",
                    "relevance": "LOW"
                },
                {
                    "id": "M9788",
                    "name": "Hormone Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M20966",
                    "name": "Antineoplastic Agents, Hormonal",
                    "relevance": "LOW"
                },
                {
                    "id": "M3032",
                    "name": "Anabolic Androgenic Steroids",
                    "relevance": "LOW"
                },
                {
                    "id": "M25605",
                    "name": "Anabolic Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}